Abstract| Volume 32, ISSUE 2, P240, April 2019

5. Premature Height Deceleration: A Risk in Transmasculine Youth

      Increasing numbers of transmasculine (TM) youth (transgender and gender diverse (TGD) youth assigned female at birth) are avoiding puberty with endogenous hormones and utilizing GnRH analogs followed by masculinizing gender affirming hormone therapy (GAHT). Clinicians providing early hormone care must monitor development, including growth. Growth spurts and final adult height are determined by numerous factors including parental heights, timing of puberty, and hormonal factors. We have noted anecdotally that a high percentage of TM youth attain their adult heights early. Few studies have systematically assessed growth variations in TGD youth, and little is known about the effects of therapies on height outcomes. The goal of this study is to assess growth patterns in TM youth before and after GnRH analog therapy and various types of GAHT.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Pediatric and Adolescent Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect